Morepen Laboratories Limited , a prominent player in the pharmaceutical industry, has announced significant strategic moves that will reshape its business portfolio and focus. The company has executed two major transactions involving its subsidiary, Dr. Morepen Limited (DML), which will result in a substantial change in its shareholding structure and business direction.

Stake Sale in Dr. Morepen Limited

Morepen Laboratories has sold 1.53 crore equity shares of DML to related party entities for ₹30.65 crore. This transaction has reduced Morepen's shareholding in DML from 80.00% to 49.91%, causing DML to cease being a subsidiary of Morepen Laboratories.

The company stated that this move is part of its strategy to focus on its core Active Pharmaceutical Ingredient (API) business. Morepen Laboratories noted that DML's over-the-counter (OTC) business has not meaningfully contributed to the company's performance over the past two decades and requires substantial resources for growth.

Acquisition of Groom Town Private Limited

In a related development, DML has executed an agreement to acquire 100% equity of Groom Town Private Limited for ₹153.01 crore. This acquisition will be financed through a fresh equity issuance of 7.64 crore shares by DML. As a result of this transaction, Morepen Laboratories' stake in DML will further reduce to 19.94%.

Groom Town Private Limited operates aspirational consumer and personal-care brands with a robust distribution network across various e-commerce platforms, including Blinkit, Zepto, Amazon, and Flipkart.

Strategic Rationale and Valuation

The company explained that these strategic moves are aimed at breaking into the high-velocity FMCG space, gaining synergies in procurement, innovation, and marketing, and diversifying its revenue mix to improve margins. The acquisition of Groom Town is expected to support DML's long-term goal of broadening its portfolio in wellness, consumer goods, and personal-care segments.

Both transactions were valued by independent registered valuers to ensure fair pricing. The equity valuation of DML and Groom Town, along with the relative fair exchange ratio for the transactions, was determined through valuation reports from Independent IBBI's Registered Valuers.

Impact on Shareholding Structure

The transactions will significantly alter the shareholding structure of DML. Following the stake sale and the acquisition of Groom Town, the shareholding pattern of DML will be as follows:

*Inclusive of 10,000 shares held as a beneficial owner.

These strategic moves mark a significant shift in Morepen Laboratories' business focus, as the company aims to optimize its portfolio and capitalize on emerging market opportunities in the consumer goods and personal care segments.

Morepen Laboratories Limited (NSE: MOREPENLAB, BSE: 500288) has announced a strategic move to strengthen its presence in the medical devices sector through the formation of a new step-down subsidiary. The company's board of directors has approved the establishment of SIGMACHECK HEALTH PRIVATE LIMITED, marking a significant expansion in Morepen's business portfolio.

Key Highlights

• New Subsidiary: SIGMACHECK HEALTH PRIVATE LIMITED will be incorporated as a wholly-owned subsidiary of Morepen Medipath Limited (MML), which is itself a subsidiary of Morepen Laboratories Limited.
• Focus Area: The new entity will specialize in medical devices to address growing market demands.
• Investment: Morepen Medipath Limited will subscribe to 10,000 shares of SIGMACHECK HEALTH at Rs. 10.00 each, totaling an initial investment of Rs. 1,00,000.00.
• Ownership Structure: Morepen Laboratories will indirectly hold a 60% equity stake in the new subsidiary through its ownership of Morepen Medipath Limited.

Strategic Expansion

The formation of SIGMACHECK HEALTH PRIVATE LIMITED represents a calculated move by Morepen Laboratories to capitalize on the expanding medical devices market. This step-down subsidiary is expected to enhance the company's capabilities in developing and manufacturing innovative medical devices, potentially opening up new revenue streams and market opportunities.

Corporate Structure

Morepen Laboratories Limited will serve as the ultimate holding company for the new entity. The corporate structure will be as follows:

1. Morepen Laboratories Limited (Parent Company)
2. Morepen Medipath Limited (Subsidiary of Morepen Laboratories)
3. SIGMACHECK HEALTH PRIVATE LIMITED (Wholly-owned subsidiary of Morepen Medipath)

Regulatory Compliance

The company has made this announcement in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The exact date of incorporation for SIGMACHECK HEALTH PRIVATE LIMITED will be communicated in due course, as stated in the company's regulatory filing.

Market Implications

This strategic move by Morepen Laboratories reflects the company's commitment to diversification and growth in the healthcare sector. By entering the medical devices segment more aggressively, Morepen is positioning itself to take advantage of the increasing demand for healthcare products and services in India and potentially in global markets.

Investors and industry observers will be keenly watching how this new subsidiary contributes to Morepen Laboratories' overall business performance and market position in the coming years.